EDGEWISE THERAPEUTICS INC (EWTX)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharmaceutical company developing oral, precision small molecule medicines for the treatment of serious cardiovascular diseases.
What EDGEWISE THERAPEUTICS INC does
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule precision medicines for severe cardiovascular diseases. The company utilizes a proprietary drug discovery platform to develop oral, selective cardiac sarcomere modulators. Its pipeline is led by EDG-7500, which is in late-stage clinical trials for hypertrophic cardiomyopathy, and EDG-15400, targeting heart failure with preserved ejection fraction.
Themes: cardiovascular diseases, hypertrophic cardiomyopathy (HCM), heart failure with preserved ejection fraction (HFpEF), precision medicine
Fundamentals
- Price$44.72 as of 2026-08-24 close
- Market cap$4.9B as of 2026-08-24
- 1-year return+201.1% 2025-08-22 close $14.85 → 2026-08-24 close $44.72
- P/En/a earnings data not available
- ROE-39.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.23 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How EWTX compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
EWTX is in the Health Care Short-term Top 10.
Health Care Short-term Top 10 — since 18 Aug 2026
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
64.3 #65 of 1,698 scored · #17 of 236 in Health Care
Volume and participation 73rd: it gapped 6.8% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; trend 66th: it is trading 8.5% above its 50-day average, the short-term trend line; weakest is setup 56th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 10% of it.
In this list since 18 Aug 2026 — currently 4th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 7, score 67.2.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How EDGEWISE THERAPEUTICS INC looks technically
EDGEWISE THERAPEUTICS INC (EWTX) is trading 41.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 184 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 4 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 41.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +41.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $41.21 | $41.21 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $31.69 | $31.69 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 41.975. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 184 trading days ago — a "golden cross", a bullish long-term signal | 184 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 56.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($41.98 to $46.59) — its "stochastic" reading is 59 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 59.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $48.40 | $48.40 |
|---|---|---|
| From the 52-week high | it is 7.6% below its 52-week high (its highest price of the past year) | -7.6% |
| Above the 52-week low | it is 230.6% above its 52-week low (its lowest price of the past year) | +230.7% |
| Below the 52-week high | it is 7.6% below its highest point of the past year | 7.6% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $48.40 (set on 2026-07-09) | $48.40 |
| Given back of the 52-week move | over the past year its closes ranged ($13.70 to $48.35), and it has given back only a small part of its rise from last year’s low — 10% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.83 to $26.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 10.5% |
| From the all-time high | it is 7.6% below its all-time high | -7.6% |
| Nearest price level | it is trading 5.7% above a support level at $42.18 — a price it turned at twice since 2026-07-27, most recently on 2026-08-14. Since 2024-08-26 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.7% |
| All-time low | its lowest closing price on record is $5.12 (set on 2023-11-10) | $5.12 |
| Above the all-time low | it is 773.4% above its all-time low | +773.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 42nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.40 between its high and its low — about 5.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.40 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $38.71 and $47.51 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $38.71 – $43.11 – $47.51 |
| Typical daily range (% of price) | its price moves about 5.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.4% |
| Stretch from the 200-day average | it is trading 5.4 daily ranges above its 200-day average price (41.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.85× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.6% since the prior reading | +0.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-24 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 6.8% above the previous close 14 sessions ago and has not traded back through the level it left behind at 38.38 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.8% |
| Gap filled | a 3.3% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +3.3% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 6.2 percentage points (the stock gained 9.5% while the market gained 3.3%) | +6.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 34.4 percentage points (the stock gained 36.8% while the market gained 2.4%) | +34.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 33.6 percentage points (the stock gained 44.7% while the market gained 11.1%) | +33.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 182.8 percentage points (the stock gained 201.1% while the market gained 18.3%) | +182.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.5% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.4% of the share price. | +8.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $35.17 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +27.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $44.36 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +0.8% |
Price levels it has turned at before
EWTX last closed at $44.72 on 2026-08-24. Since 2024-08-26 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $42.18 | Support | 5.7% below the last close | turned there twice · 2026-07-27 to 2026-08-14 |
| $38.24 | Support | 14.5% below the last close | turned there twice · 2024-11-11 to 2026-07-02 |
| $36.93 | Support | 17.4% below the last close | turned there three times · 2024-10-17 to 2026-08-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $41.98.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $51.02 and $56.62 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $41.98.
This reading has stood for 2 trading days, since 2026-08-21.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · beating the market · Trading above the Ichimoku cloud · Elliott wave 3 candidates | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.54 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$51.15 range $36.00 – $66.00; median $52.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EWTX
- Consensus EPS estimate$2.81 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of operating losses and an accumulated deficit.","Dependence on the successful development and regulatory approval of clinical-stage product candidates.","Risks related to macroeconomic and geopolitical developments impacting clinical trials and capital markets."]
What changed in the latest 10-Q
AI-assisted comparison of EWTX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds reference to Annual Report filed on February 26, 2026, versus older filing reference to March 3, 2025
- Newer filing adds statement that EDG-15400 'expects to initiate a Phase 2 trial in HFpEF in the second half of 2026'
- Newer filing describes sevasemten as 'selective, fast myofiber (type II) myosin small molecule inhibitor' with added detail on myofiber type
- Newer filing identifies company as 'late-stage clinical biopharmaceutical company' versus older filing as 'clinical-stage biopharmaceutical company'
- Newer filing adds subsection header 'Operating expenses' before R&D expenses section
- Removed:
- Older filing includes reference to 'U.S federal government shutdown' in macroeconomic developments; newer filing removes this specific reference
- Older filing includes phrase 'so that the Company can be prepared to react to new developments as they arise' in macroeconomic section; newer filing removes this phrase
- Older filing states net losses were '$40.7 million and $117.6 million for the three and nine months ended September 30, 2025' and comparative prior year figures; newer filing replaces with '$49.0 million and $40.8 million for the three months ended March 31, 2026 and 2025'
- Older filing references accumulated deficit of '$496.2 million' as of September 30, 2025; newer filing states '$595.4 million' as of March 31, 2026
- Older filing states cash and marketable securities of '$563.3 million'; newer filing states '$499.6 million'
- Older filing includes sentence 'We track our direct research and development expenses on a program-by-program basis once a lead compound ha' (truncated); newer filing removes this incomplete sentence
- Reworded:
- Sevasemten description changed from 'fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage' to 'selective, fast myofiber (type II) myosin small molecule inhibitor designed to address contraction-induced muscle injury'
- Clinical trial description changed from 'multiple Phase 2 clinical trials' to 'multiple late-stage clinical trials'
- HCM description changed from 'non-obstructive' to 'nonobstructive' (hyphenation removed)
- Macroeconomic developments language changed from 'evaluating potential impacts' to 'evaluating potential impacts' (no substantive change in phrasing)
- R&D expenses conclusion changed from 'through the remainder of the clinical development phases' to 'through later-stage clinical development phases and potentially registrational activities'
- Notes:
- Comparison involves two different quarterly periods (Q3 2025 ending September 30, 2025 versus Q1 2026 ending March 31, 2026), so financial figures and some program status updates reflect different time periods rather than pure editorial changes
- Older filing text appears truncated at end of provided excerpt, limiting full assessment of removals
Risk Factors
- Added:
- Added section header 'Risks Related to Regulatory Approval and Other Legal Compliance Matters' in the newer filing (2026-05-07) to group the FDA/EMA regulatory approval risk factor separately
- Added section header 'Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business' in the newer filing (2026-05-07) to group the employee retention risk factor
- Added section header 'Risks Related to Our Intellectual Property' in the newer filing (2026-05-07) to group the intellectual property protection risk factor
- Added section header 'Risks Related to Our Dependence on Third Parties' in the newer filing (2026-05-07) to group third-party clinical trial risk factor
- Removed:
- Removed separate bullet point 'Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates' from the older filing (2025-11-06); this content is now merged into a single bullet in the newer filing
- Removed incomplete text at end of older filing (2025-11-06) regarding third-party contracting for production and reliance on third parties
- Reworded:
- Combined two separate bullet points about capital requirements into one in the newer filing (2026-05-07): 'We will require substantial additional capital to finance our operations, which may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.' versus the older filing's two separate bullets
- Added 'Risks Related to' category headers as organizational structure in the newer filing (2026-05-07) that were not present in the older filing (2025-11-06)
- Notes:
- The older filing text appears truncated at the end, making full comparison of the final risk factor incomplete
- The reorganization with new section headers in the newer filing represents structural/presentational changes rather than substantive content changes to individual risk factors
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($8M) — 1 selling insider
- Last 180 days0 buys · 5 sells ($11M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-01. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EWTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding EWTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,690,598
- Reported value $305,253,843
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
EWTX had 9,835,054 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
EWTX had 9.06% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.07 days to cover at the same settlement.
- Reported short interest (shares) 9,835,054
- Short interest (% of shares outstanding) 9.06%
- Prior settlement (shares) 10,074,332
- Reported change -2.38%
- Days to cover (reported) 12.07
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EWTX vs…
EDGEWISE THERAPEUTICS INC is found in…
Frequently asked questions
What does EDGEWISE THERAPEUTICS INC (EWTX) do?
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule precision medicines for severe cardiovascular diseases. The company utilizes a proprietary drug discovery platform to develop oral, selective cardiac sarcomere modulators. Its pipeline is led by EDG-7500, which is in late-stage clinical trials for hypertrophic cardiomyopathy, and EDG-15400, targeting heart failure with preserved ejection fraction.
What sector is EDGEWISE THERAPEUTICS INC (EWTX) in?
EDGEWISE THERAPEUTICS INC (EWTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are EDGEWISE THERAPEUTICS INC's (EWTX) competitors?
Notable peers of EDGEWISE THERAPEUTICS INC (EWTX) include Bristol Myers Squibb and Cytokinetics. This peer set is informational only — not financial advice.
Is EDGEWISE THERAPEUTICS INC (EWTX) overbought or oversold right now?
EDGEWISE THERAPEUTICS INC (EWTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EWTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.